• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News & Analysis

Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News & Analysis

Currency in USD Disclaimer

$17.12

$0.04

(0.2%)

Day's range
$16.87
Day's range
$17.13
50-day range
$16.15
Day's range
$19.31
  • Country: IL
  • ISIN: US8816242098
52 wk range
$9.35
Day's range
$19.31


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.26
  • Piotroski Score 5.00
  • Grade Overweight
  • Symbol (TEVA)
  • Company Teva Pharmaceutical Industries Limited
  • Price $17.12
  • Changes Percentage (0.2%)
  • Change $0.04
  • Day Low $16.87
  • Day High $17.13
  • Year High $19.31

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

  • Last Earnings 11/02/2017
  • Ex-Dividend for 5/16 Dividend 11/27/2017
  • Dividend Payable 12/12/2017
  • Today N/A
  • Next Earnings (Estimated) 01/29/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $22.00
  • High Stock Price Target $26.00
  • Low Stock Price Target $10.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.42
  • Trailing P/E Ratio -40.05
  • Forward P/E Ratio -40.05
  • P/E Growth -40.05
  • Net Income $-559,000,000

Income Statement

Quarterly

Annual

Latest News of TEVA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Teva Pharmaceutical Industries Limited Frequently Asked Questions

  • What were the earnings of TEVA in the last quarter?

    In the last quarter Teva Pharmaceutical Industries Limited earnings were on Wednesday, November, 6th. The Teva Pharmaceutical Industries Limited maker reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.04.

  • What is the Teva Pharmaceutical Industries Limited stock price today?

    Today's price of Teva Pharmaceutical Industries Limited is $17.12 — it has increased by +0.2% in the past 24 hours. Watch Teva Pharmaceutical Industries Limited stock price performance more closely on the chart.

  • Does Teva Pharmaceutical Industries Limited release reports?

    Yes, you can track Teva Pharmaceutical Industries Limited's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Teva Pharmaceutical Industries Limited stock forecast?

    Watch the Teva Pharmaceutical Industries Limited chart and read a more detailed Teva Pharmaceutical Industries Limited stock forecast to see what analysts suggest you do with its shares.

  • What is Teva Pharmaceutical Industries Limited stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NYSE, exchange stock trades by Teva Pharmaceutical Industries Limited stock ticker.

  • How to buy Teva Pharmaceutical Industries Limited stocks?

    Like other stocks, TEVA shares are sold on stock exchanges such as NYSE. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Teva Pharmaceutical Industries Limited's EBITDA?

    Teva Pharmaceutical Industries Limited measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Teva Pharmaceutical Industries Limited’s financial statements.

  • What is the Teva Pharmaceutical Industries Limited's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.0352770415, which equates to approximately -3.53%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Teva Pharmaceutical Industries Limited stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Teva Pharmaceutical Industries Limited's financials relevant news, and technical analysis. Teva Pharmaceutical Industries Limited's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Teva Pharmaceutical Industries Limited stock currently indicates a “sell” signal. For more insights, review Teva Pharmaceutical Industries Limited’s technical analysis.

  • A revenue figure for Teva Pharmaceutical Industries Limited for its last quarter?

    Teva Pharmaceutical Industries Limited published it's last quarterly revenues at $4.33 B.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.